Long-term follow-up of 22 psoriatic patients treated with ixekizumab after failure of secukinumab

In conclusion, ixekizumab appears to be a therapeutic option as a second IL17A-blocker in psoriasis patients who did not show a primary non-response to secukinumab.

Source: Dermatology Online Journal - March 2, 2020 Category: Dermatology Source Type: research